Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Clinical Research and Equipment Industry Analysis

UpdatedAug 17, 2026
DataAggregated Company Financials
Companies22
  • 7D3.0%
  • 3M18.3%
  • 1Y21.5%
  • YTDn/a

The Clinical Research and Equipment industry is up 3.0% in the last week, with Divi's Laboratories up 2.4%. This means that the industry has gained 21% over the past year. As for the next few years, earnings are expected to grow by 22% per annum.

Industry Valuation and Performance

Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 17 Aug 2026₹3.9t₹373.9b₹48.2b38.3x81.3x10.5x
Wed, 15 Jul 2026₹3.5t₹361.8b₹46.4b41.5x74.5x9.5x
Fri, 12 Jun 2026₹3.3t₹361.9b₹46.4b38.8x70.5x9x
Sun, 10 May 2026₹3.3t₹354.7b₹45.7b35.6x71.9x9.3x
Tue, 07 Apr 2026₹2.8t₹350.2b₹46.2b28.6x60.7x8x
Thu, 05 Mar 2026₹2.9t₹350.2b₹46.2b26.2x63.3x8.4x
Sat, 31 Jan 2026₹2.8t₹344.9b₹46.4b27.9x60.5x8.1x
Mon, 29 Dec 2025₹3.1t₹342.6b₹48.4b32.6x64.5x9.1x
Wed, 26 Nov 2025₹3.1t₹342.6b₹48.4b33.2x63.6x9x
Fri, 24 Oct 2025₹3.2t₹331.4b₹45.5b42.9x71x9.8x
Sun, 21 Sep 2025₹3.2t₹331.4b₹45.5b51.2x71.3x9.8x
Tue, 19 Aug 2025₹3.2t₹331.4b₹45.5b41.2x70.3x9.7x
Thu, 17 Jul 2025₹2.9t₹300.7b₹37.2b47.3x79.3x9.8x
Sat, 14 Jun 2025₹2.9t₹299.7b₹37.2b47.1x77.5x9.6x
Mon, 12 May 2025₹2.6t₹292.8b₹32.3b44.7x79.6x8.8x
Wed, 09 Apr 2025₹2.4t₹287.4b₹30.8b42.7x78.4x8.4x
Fri, 07 Mar 2025₹2.4t₹287.4b₹30.8b48.4x79.6x8.5x
Sun, 02 Feb 2025₹2.4t₹270.7b₹30.5b48.7x77.2x8.7x
Tue, 31 Dec 2024₹2.6t₹269.1b₹30.1b51.6x85.4x9.6x
Thu, 28 Nov 2024₹2.4t₹254.2b₹28.8b49.3x84.2x9.6x
Sat, 26 Oct 2024₹2.3t₹247.4b₹26.2b50x89.7x9.5x
Mon, 23 Sep 2024₹2.3t₹247.6b₹26.3b49.7x87.3x9.3x
Wed, 21 Aug 2024₹2.1t₹247.1b₹23.8b39.3x86.9x8.4x
Fri, 19 Jul 2024₹1.8t₹201.9b₹23.9b38.4x75.9x9x
Sun, 16 Jun 2024₹1.8t₹194.5b₹21.5b34.3x82.1x9.1x
Tue, 14 May 2024₹1.6t₹194.1b₹21.6b31.8x72.8x8.1x
Thu, 11 Apr 2024₹1.4t₹168.5b₹18.6b29.3x76.7x8.5x
Sat, 09 Mar 2024₹1.4t₹168.5b₹18.6b31.1x74x8.2x
Mon, 05 Feb 2024₹1.4t₹166.6b₹19.0b32.6x74.7x8.5x
Wed, 03 Jan 2024₹1.5t₹155.9b₹18.1b23.5x80.9x9.4x
Fri, 01 Dec 2023₹1.4t₹155.9b₹18.1b22.3x77.3x9x
Sun, 29 Oct 2023₹1.3t₹156.1b₹19.8b23x63.6x8.1x
Tue, 26 Sep 2023₹1.4t₹154.7b₹19.7b25.2x70.7x9x
Thu, 24 Aug 2023₹1.4t₹154.7b₹19.7b26.1x70.9x9x
Price to Earnings Ratio

70.9x


Total Market Cap: ₹1.4tTotal Earnings: ₹19.7bTotal Revenue: ₹154.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Clinical Research and Equipment Industry Price to Earnings3Y Average 74.9x202420252026
Current Industry PE
  • Investors are optimistic on the Indian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 79.9x which is higher than its 3-year average PE of 74.9x.
  • The 3-year average PS ratio of 9.0x is lower than the industry's current PS ratio of 10.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 36% per year over the last three years.
  • Revenues for these companies have grown 34% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Indian Clinical Research and Equipment compare with similar industries?

IN Market-0.35%
Healthcare-0.17%
Life Sciences3.01%
Clinical Research and Equipment3.01%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹8.48k2.4%
+₹53.6b		38.2%PE76.9x
ANTHEM Anthem Biosciences₹890.105.8%
+₹27.7b		7.9%PE87x
SAILIFE Sai Life Sciences₹1.45k6.2%
+₹18.0b		63.3%PE85x
530239 Suven Life Sciences₹342.357.6%
+₹6.4b		44.8%PS1024.4x
INNOVACAP Innova Captab₹1.04k9.7%
+₹5.2b		14.4%PE38.5x

Latest News

DCAL
₹190.66
Dishman Carbogen Amcis
7D
-1.2%
1Y
-28.8%
INNOVACAP
₹1,036.00
Innova Captab
7D
9.7%
1Y
14.4%
Analysis Article • Aug 15

Earnings Beat: Innova Captab Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Innova Captab Limited ( NSE:INNOVACAP ) investors will be delighted, with the company turning in some strong numbers...
SYNGENE
₹401.45
Syngene International
7D
-0.6%
1Y
-39.9%
Narrative Update • Aug 14

SYNGENE: Earnings Guidance And Margin Outlook Will Pressure Future Returns

Analysts have trimmed their price target for Syngene International from ₹410 to ₹340, citing updated assumptions on revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Syngene International Syngene International issued earnings guidance for fiscal 2027, indicating an expected single digit decline in revenue in rupee terms and EBITDA margins in the mid 20% range.
AKUMS
₹726.60
Akums Drugs and Pharmaceuticals
7D
4.2%
1Y
54.4%
Narrative Update • Aug 11

AKUMS: Upcoming Board Schedule And Special Dividend Will Shape Earnings Outlook

Analysts have lifted their price target on Akums Drugs and Pharmaceuticals from ₹730 to ₹780, citing updated estimates that reflect the new fair value, an adjusted discount rate, revised revenue growth assumptions, higher profit margin forecasts and a lower future P/E multiple. What's in the News Akums Drugs and Pharmaceuticals has scheduled a board meeting on Aug 08, 2026, at 13:30 Indian Standard Time to consider and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.
TARSONS
₹360.30
Tarsons Products
7D
15.4%
1Y
4.8%
WINDLAS
₹949.45
Windlas Biotech
7D
7.5%
1Y
-9.4%
SAILIFE
₹1,449.90
Sai Life Sciences
7D
6.2%
1Y
63.3%
Narrative Update • Aug 10

SAILIFE: Upcoming Board Review And Updated Assumptions Will Shape Measured Outlook

Analysts have lifted their price target on Sai Life Sciences from ₹1,275 to about ₹1,369, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that feed into their fair value models. What’s in the News for Sai Life Sciences Sai Life Sciences has scheduled a board meeting for August 6, 2026.
DIVISLAB
₹8,477.00
Divi's Laboratories
7D
2.4%
1Y
38.2%
Narrative Update • Aug 06

DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk

Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
544184
₹134.00
Borosil Scientific
7D
-5.4%
1Y
-7.4%
530239
₹342.35
Suven Life Sciences
7D
7.6%
1Y
44.8%
ONESOURCE
₹1,559.20
OneSource Specialty Pharma
7D
-1.1%
1Y
-16.9%
Analysis Article • Jul 29

Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results

It's been a good week for OneSource Specialty Pharma Limited ( NSE:ONESOURCE ) shareholders, because the company has...
ANTHEM
₹890.10
Anthem Biosciences
7D
5.8%
1Y
7.9%
New Narrative • Jul 28

Capacity Expansion And Modalities Shift Will Support Stronger Long-Term Earnings Visibility

Catalysts About Anthem Biosciences Anthem Biosciences is a contract research, development and manufacturing organization with a large focus on CRDMO services and specialty ingredients across small molecules, peptides, fermentation and related modalities. What are the underlying business or industry changes driving this perspective?
540729
₹19.64
Vanta Bioscience
7D
-9.7%
1Y
-23.4%
FABTECH
₹147.77
Fabtech Technologies
7D
-0.6%
1Y
n/a
524394
₹616.30
Vimta Labs
7D
-5.3%
1Y
-6.7%
511509
₹20.10
Vivo Bio Tech
7D
-7.5%
1Y
-45.8%